BBP-418
Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Phase 3Active (Positive Interim)
Key Facts
Indication
Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Phase
Phase 3
Status
Active (Positive Interim)
Company
About BridgeBio Pharma
BridgeBio Pharma is a clinical-stage biotech with a mission to translate genetic insights into life-changing medicines for rare diseases and cancers. The company has achieved significant milestones, including three FDA approvals, a robust late-stage pipeline with six Phase 3 trials conducted, and a market valuation reflecting strong investor confidence. Its core strategy leverages a decentralized hub-and-spoke operational model to pursue multiple high-precision programs simultaneously, targeting conditions with clear genetic etiology and significant unmet need.
View full company profile